Background: In the United States, annual vaccination against seasonal influenza is recommended for all people ages ≥ 6 months. Vaccination coverage assessments can identify populations less protected from influenza morbidity and mortality and help to tailor vaccination efforts. Within the Vaccine Safety Datalink population ages ≥ 6 months, we report influenza vaccination coverage for the 2017-18 through 2022-23 seasons.
Methods: Across eight health systems, we identified influenza vaccines administered from August 1 through March 31 for each season using electronic health records linked to immunization registries. Crude vaccination coverage was described for each season, overall and by self-reported sex; age group; self-reported race and ethnicity; and number of separate categories of diagnoses associated with increased risk of severe illness and complications from influenza (hereafter referred to as high-risk conditions). High-risk conditions were assessed using ICD-10-CM diagnosis codes assigned in the year preceding each influenza season.
Results: Among individual cohorts of more than 12 million individuals each season, overall influenza vaccination coverage increased from 41.9 % in the 2017-18 season to a peak of 46.2 % in 2019-20, prior to declaration of the COVID-19 pandemic. Coverage declined over the next three seasons, coincident with widespread SARS-CoV-2 circulation, to a low of 40.3 % in the 2022-23 season. In each of the six seasons, coverage was lowest among males, 18-49-year-olds, non-Hispanic Black people, and those with no high-risk conditions. While decreases in coverage were present in all age groups, the declines were most substantial among children: 2022-23 season coverage for children ages six months through 8 years and 9-17 years was 24.5 % and 22.4 % (14 and 10 absolute percentage points), respectively, less than peak coverage achieved in the 2019-20 season.
Conclusions: Crude influenza vaccination coverage increased from 2017 to 18 through 2019-20, then decreased to the lowest level in the 2022-23 season. In this insured population, we identified persistent disparities in influenza vaccination coverage by sex, age, and race and ethnicity. The overall low coverage, disparities in coverage, and recent decreases in coverage are significant public health concerns.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10867768 | PMC |
http://dx.doi.org/10.1016/j.vaccine.2023.10.023 | DOI Listing |
J Infect Dis
January 2025
Center for Cervical Cancer Elimination, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Background: Most countries in the world have launched human papillomavirus (HPV) vaccination programmes and declining prevalences of HPV are reported. We aimed to disentangle the influences of calendar time, birth cohort and age by analysing HPV prevalences in the population-based cervical screening programme using age-period-cohort modelling.
Methods: All 836,314 primary HPV-based cervical screening tests from women aged 23-64 between 2014-2023 in the capital region of Sweden were identified in the Swedish National Cervical Screening Registry.
Cureus
December 2024
Otolaryngology and Public Health Sciences, Henry Ford Health System, Detroit, USA.
Introduction Studies assessing human papillomavirus (HPV) vaccination uptake in survivors of childhood, adolescent, and young adult (CAYA) cancers are sparse. We examined HPV vaccine uptake between survivors of CAYA cancer aged 18-35 and 18-35-year-old respondents without a cancer diagnosis in the United States. Methods We used the 2017-2018 National Health Interview Survey, a national, annual cross-sectional national dataset that monitors health-related information on the non-institutionalized civilian population in the United States.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Department of Pharmaceutical Management and Marketing, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Introduction: Pharmacy-based vaccination services are now available in 56 countries, including Romania, that started administering the flu-vaccines in the community pharmacies from 2022. Assessing how pharmacists managed this new pharmaceutical service in Romania is the subject of this study.
Methods: A cross-sectional study was conducted among all the pharmacies from Romania that were authorized to provide this service (442 pharmacies, from which 53 were in rural areas).
J Community Hosp Intern Med Perspect
November 2024
Department of Medicine, Abbas Institute of Medical Sciences, Muzaffrabad, Pakistan.
Objective: This study aimed to investigate healthcare workers (HCWs) acceptance of the HMPXV vaccine in Pakistan and identify influencing factors.
Methods: A cross-sectional survey of 4257 HCWs assessed vaccine acceptance across demographics, ethnicity, marital status, specialty, medical conditions, and education. Logistic regression identified predictors of acceptance.
Vaccine
January 2025
Shenzhen Key Laboratory of Pathogenic Microbes and Biosafety, Shenzhen campus of Sun Yat-sen University, Shenzhen 518107, China; School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China; Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou 510080, China. Electronic address:
Objective: Seasonal influenza vaccine is effective to reduce the risk of hospitalization and death in vulnerable older persons, but the coverage of influenza vaccine remains low in these population in China. This study thus aimed to investigate how adults' vaccine literacy affects their intention to recommend influenza vaccination to older family members in China.
Methods: A cross-sectional survey was performed in China during October 7 to 16, 2023 through a web-based questionnaire.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!